Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients

Ana Maria Wagner, Antonio Perez, Edgar Zapico, Jordi Ordóñez-Llanos

Research output: Contribution to journalArticleResearchpeer-review

47 Citations (Scopus)


OBJECTIVE - To compare non-HDL cholesterol (HDLc) and apolipoprotein B (apoB) in the identification of nonconventional high-risk dyslipidemic phenotypes in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Total cholesterol and triglycerides, HDLc, LDL cholesterol, non-HDLc, apolipoprotein B (apoB), and LDL size were determined in 122 type 2 diabetic patients (68% male, aged 59.6 ± 9.7 years, and HbA1c 7.5% [range 5.2-16.0]). They were then classified as normo- and hypertriglyceridemic if their triglyceride concentrations were below/above 2.25 mmol/l, as normo/hyper-non-HDLc if non-HDLc concentrations were below/above 4.13 mmol/l, and as normo- and hyperapoB if apoB concentrations were below/above 0.97 g/l. Both classifications were compared (concordance assessed with the κ index), and low HDLc and LDL phenotype B were identified in each category. RESULTS - A total of 26 patients were hypertriglyceridemic and 96 were normotriglyceridemic. All hypertriglyceridemic subjects had increased non-HDLc, whereas 24 had increased apoB (κ = 0.95). In the normotriglyceridemic group, 44 had increased non-HDLc, 68 had increased apoB, and 25 of the 52 patients with normal non-HDLc had increased apoB (κ = 0.587). Low HDLc and LDL phenotype B were similarly distributed into the equivalent categories. CONCLUSIONS - Non-HDLc and apoB are equivalent risk markers in hypertriglyceridemic patients, but apoB identifies additional patients with high-risk dyslipidemic phenotypes in normotriglyceridemic type 2 diabetic patients. © 2003 by the American Diabetes Association.
Original languageEnglish
Pages (from-to)2048-2051
JournalDiabetes Care
Issue number7
Publication statusPublished - 1 Jul 2003


Dive into the research topics of 'Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients'. Together they form a unique fingerprint.

Cite this